Literature DB >> 14654356

Cell cycle dependent intracellular distribution of two spliced isoforms of TCP/ILF3 proteins.

You Hai Xu1, Tatyana Leonova, Gregory A Grabowski.   

Abstract

TCP80 is an approximately 80kDa mammalian cytoplasmic protein that binds to a set of mRNAs and inhibits their translation in vitro and ex vivo. This protein has high sequence similarity to interleukin-2 enhancer-binding factors (NF90/ILF3) and the M-phase phosphoprotein (MPP4)/DRBP76. A 110kDa immunologic isoform of TCP80/NF90/MPP4/DRBP76, termed TCP110, also is present in cytoplasm and nuclei of many types of cells. A cDNA sequence coding for TCP110 was derived by 5(')RACE. The TCP110 sequence is identical to ILF3. The gene coding for TCP110/ILF3 mapped to human chromosome 19 and the gene organization was analyzed using TCP80 and TCP110/ILF3 cDNA sequences. The TCP/ILF3 gene spans >34.8kb and contains 21 exons. At least one alternatively spliced product involving exons 19-21 exists and predicts the formation of either TCP80 or TCP110/ILF3. However, the functional relationships of TCP80 and TCP110/ILF3 required elucidation. The metabolic turnover rates and subcellular distribution of TCP80 and TCP110/ILF3 during the cell cycle showed TCP80 to be relatively stable (t(1/2)=5 days) in the cytoplasmic compartment. In comparison, TCP110/ILF3 migrated between the cytoplasmic and nuclear compartments during the cell cycle. The TCP110 C-terminal segment contains an additional nuclear localizing signal that plays a role in its nuclear translocation. This study indicates that the multiple cellular functions, i.e., translation control, interleukin-2 enhancer binding, or cell division, of TCP/ILF3 are fulfilled by alternatively spliced isoforms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654356     DOI: 10.1016/j.ymgme.2003.09.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  8 in total

1.  The RNA binding complexes NF45-NF90 and NF45-NF110 associate dynamically with the c-fos gene and function as transcriptional coactivators.

Authors:  Tomoyoshi Nakadai; Aya Fukuda; Miho Shimada; Ken Nishimura; Koji Hisatake
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

2.  Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control.

Authors:  Deyu Guan; Nihal Altan-Bonnet; Andrew M Parrott; Cindy J Arrigo; Quan Li; Mohammed Khaleduzzaman; Hong Li; Chee-Gun Lee; Tsafi Pe'ery; Michael B Mathews
Journal:  Mol Cell Biol       Date:  2008-05-05       Impact factor: 4.272

3.  L-Ilf3 and L-NF90 traffic to the nucleolus granular component: alternatively-spliced exon 3 encodes a nucleolar localization motif.

Authors:  Wildriss Viranaicken; Laila Gasmi; Alexandre Chaumet; Christiane Durieux; Virginie Georget; Philippe Denoulet; Jean-Christophe Larcher
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

4.  Novel rapidly evolving hominid RNAs bind nuclear factor 90 and display tissue-restricted distribution.

Authors:  Andrew M Parrott; Michael B Mathews
Journal:  Nucleic Acids Res       Date:  2007-09-13       Impact factor: 16.971

5.  Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation.

Authors:  Rong Jia; Masahiko Ajiro; Lulu Yu; Philip McCoy; Zhi-Ming Zheng
Journal:  RNA       Date:  2019-02-22       Impact factor: 4.942

6.  Regulated dicing of pre-mir-144 via reshaping of its terminal loop.

Authors:  Renfu Shang; Dmitry A Kretov; Scott I Adamson; Thomas Treiber; Nora Treiber; Jeffrey Vedanayagam; Jeffrey H Chuang; Gunter Meister; Daniel Cifuentes; Eric C Lai
Journal:  Nucleic Acids Res       Date:  2022-07-22       Impact factor: 19.160

Review 7.  NF90 in posttranscriptional gene regulation and microRNA biogenesis.

Authors:  Kiyoshi Masuda; Yuki Kuwano; Kensei Nishida; Kazuhito Rokutan; Issei Imoto
Journal:  Int J Mol Sci       Date:  2013-08-19       Impact factor: 5.923

8.  High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma.

Authors:  Zhangyan Xu; Hua Huang; Xing Li; Cheng Ji; Yifei Liu; Xiaojuan Liu; Jun Zhu; Zhendong Wang; Haijian Zhang; Jiahai Shi
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.